Emerging role of transforming growth factor-β-regulated long non-coding RNAs in prostate cancer pathogenesis

Cancer Pathog Ther. 2022 Dec 24;1(3):195-204. doi: 10.1016/j.cpt.2022.12.003. eCollection 2023 Jul.

Abstract

Prostate cancer (PCa) is the most common malignancy in men. Despite aggressive therapy involving surgery and hormonal treatments, the recurrence and emergence of metastatic castration-resistant prostate cancer (CRPCa) remain a major challenge. Dysregulation of the transforming growth factor-β (TGF-β) signaling pathway is crucial to PCa development and progression. This also contributes to androgen receptor activation and the emergence of CRPC. In addition, TGF-β signaling regulates long non-coding RNA (lncRNA) expression in multiple cancers, including PCa. Here, we discuss the complex regulatory network of lncRNAs and TGF-β signaling in PCa and their potential applications in diagnosing, prognosis, and treating PCa. Further investigations on the role of lncRNAs in the TGF-β pathway will help to better understand PCa pathogenesis.

Keywords: Androgen deprivation therapy; Androgen-independent prostate cancer; Benign prostatic hyperplasia; Castration-resistant prostate cancer; LncRNA; Prostate cancer; Prostate-specific antigen; TGF-β.

Publication types

  • Review